103 related articles for article (PubMed ID: 25489726)
1. Quantification of serum MET in non-small-cell lung cancer and its clinical significance.
Li D; Li F; Wu Y; Zhou D; Chen H
Clin Biochem; 2015 Feb; 48(3):110-4. PubMed ID: 25489726
[TBL] [Abstract][Full Text] [Related]
2. Quantification of serum HBXAP DNA in lung cancer patients by quantitative fluorescent polymerase chain reaction.
Hou YL; Chen H; Ge MJ; Li FZ; Xue CJ; Wu YF; Luo HX
Mol Biol Rep; 2013 Jun; 40(6):4091-6. PubMed ID: 23456648
[TBL] [Abstract][Full Text] [Related]
3. Clinical significance of serum mitochondrial DNA in lung cancer.
Hou YL; Chen JJ; Wu YF; Xue CJ; Li FZ; Zheng Q; Chen H
Clin Biochem; 2013 Oct; 46(15):1474-7. PubMed ID: 23611926
[TBL] [Abstract][Full Text] [Related]
4. Quantification of serum SOX2 DNA with FQ-PCR potentially provides a diagnostic biomarker for lung cancer.
Wu Y; Du X; Xue C; Li D; Zheng Q; Li X; Chen H
Med Oncol; 2013 Dec; 30(4):737. PubMed ID: 24126941
[TBL] [Abstract][Full Text] [Related]
5. Serum reactive oxygen species modulator 1 (Romo1) as a potential diagnostic biomarker for non-small cell lung cancer.
Lee SH; Lee JS; Lee EJ; Min KH; Hur GY; Lee SH; Lee SY; Kim JH; Lee SY; Shin C; Shim JJ; Kang KH; In KH
Lung Cancer; 2014 Aug; 85(2):175-81. PubMed ID: 24951318
[TBL] [Abstract][Full Text] [Related]
6. Circulating plasma DNA as diagnostic biomarker in non-small cell lung cancer.
Paci M; Maramotti S; Bellesia E; Formisano D; Albertazzi L; Ricchetti T; Ferrari G; Annessi V; Lasagni D; Carbonelli C; De Franco S; Brini M; Sgarbi G; Lodi R
Lung Cancer; 2009 Apr; 64(1):92-7. PubMed ID: 18804892
[TBL] [Abstract][Full Text] [Related]
7. Combined detection of CEA, CK-19 and c-met mRNAs in peripheral blood: a highly sensitive panel for potential molecular diagnosis of non-small cell lung cancer.
Sheu CC; Chang MY; Chang HC; Tsai JR; Lin SR; Chang SJ; Hwang JJ; Huang MS; Chong IW
Oncology; 2006; 70(3):203-11. PubMed ID: 16809939
[TBL] [Abstract][Full Text] [Related]
8. Quantification of free circulating DNA as a diagnostic marker in lung cancer.
Sozzi G; Conte D; Leon M; Ciricione R; Roz L; Ratcliffe C; Roz E; Cirenei N; Bellomi M; Pelosi G; Pierotti MA; Pastorino U
J Clin Oncol; 2003 Nov; 21(21):3902-8. PubMed ID: 14507943
[TBL] [Abstract][Full Text] [Related]
9. Serum biomarkers facilitate the recognition of early- stage cancer and may guide the selection of surgical candidates: a study of carcinoembryonic antigen and tissue polypeptide antigen in patients with operable non-small cell lung cancer.
Buccheri G; Ferrigno D
J Thorac Cardiovasc Surg; 2001 Nov; 122(5):891-9. PubMed ID: 11689793
[TBL] [Abstract][Full Text] [Related]
10. Clinical significance of serum transforming growth factor-β1 in lung cancer.
Hou YL; Chen H; Dong ZH; Xue CJ; Wu YF; Luo HX; Wu YC; Li CH
Cancer Epidemiol; 2013 Oct; 37(5):750-3. PubMed ID: 23727122
[TBL] [Abstract][Full Text] [Related]
11. The value of serum Cyfra21-1 as a biomarker in the diagnosis of patients with non-small cell lung cancer: a meta-analysis.
Cui C; Sun X; Zhang J; Han D; Gu J
J Cancer Res Ther; 2014 Nov; 10 Suppl():C131-4. PubMed ID: 25450270
[TBL] [Abstract][Full Text] [Related]
12. Serum cyfra21-1 as a biomarker in patients with nonsmall cell lung cancer.
Zhao H; Shi X; Liu J; Chen Z; Wang G
J Cancer Res Ther; 2014 Nov; 10 Suppl():C215-7. PubMed ID: 25450285
[TBL] [Abstract][Full Text] [Related]
13. Cytokeratin 19 fragment CYFRA 21-1 compared with carcinoembryonic antigen, squamous cell carcinoma antigen and neuron-specific enolase in lung cancer. Results of an international multicentre study.
Ebert W; Dienemann H; Fateh-Moghadam A; Scheulen M; Konietzko N; Schleich T; Bombardieri E
Eur J Clin Chem Clin Biochem; 1994 Mar; 32(3):189-99. PubMed ID: 7518259
[TBL] [Abstract][Full Text] [Related]
14. [Detection and diagnostic value of serum carcinoembryonic antigen and cytokeratin 19 fragment in lung cancer patients].
Hang ZQ; Zheng MF; Huang JH
Zhonghua Zhong Liu Za Zhi; 2011 Nov; 33(11):847-9. PubMed ID: 22335951
[TBL] [Abstract][Full Text] [Related]
15. Use of a new generation of capillary electrophoresis to quantify circulating free DNA in non-small cell lung cancer.
Chiappetta C; Anile M; Leopizzi M; Venuta F; Della Rocca C
Clin Chim Acta; 2013 Oct; 425():93-6. PubMed ID: 23892142
[TBL] [Abstract][Full Text] [Related]
16. The diagnostic value of circulating stanniocalcin-1 mRNA in non-small cell lung cancer.
Du YZ; Gu XH; Li L; Gao F
J Surg Oncol; 2011 Dec; 104(7):836-40. PubMed ID: 21656524
[TBL] [Abstract][Full Text] [Related]
17. Value of tumour and inflammatory markers in lung cancer.
Oremek GM; Sauer-Eppel H; Bruzdziak TH
Anticancer Res; 2007; 27(4A):1911-5. PubMed ID: 17649794
[TBL] [Abstract][Full Text] [Related]
18. Prospective study of urinary and serum cross-linked N-telopeptide of type I collagen (NTx) for diagnosis of bone metastasis in patients with lung cancer.
Tamiya M; Tokunaga S; Okada H; Suzuki H; Kobayashi M; Sasada S; Okamoto N; Morishita N; Matsuura Y; Miyamoto N; Hattori M; Taira K; Daga H; Takeda K; Hirashima T
Clin Lung Cancer; 2013 Jul; 14(4):364-9. PubMed ID: 23276824
[TBL] [Abstract][Full Text] [Related]
19. [Clinical value of combined detection of serum tumor markers in lung cancer diagnosis].
Chen F; Li WM; Wang DM; Gao SS; Bao Y; Chen WB; Liu D
Sichuan Da Xue Xue Bao Yi Xue Ban; 2008 Sep; 39(5):832-5. PubMed ID: 19024326
[TBL] [Abstract][Full Text] [Related]
20. Cytokeratins as serum markers in lung cancer: a comparison of CYFRA 21-1 and TPS.
Pujol JL; Grenier J; Parrat E; Lehmann M; Lafontaine T; Quantin X; Michel FB
Am J Respir Crit Care Med; 1996 Sep; 154(3 Pt 1):725-33. PubMed ID: 8810612
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
